Review



tgf β2 rii  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    R&D Systems tgf β2 rii
    Figure 3. Effects of co-inhibition of <t>TGF-B,</t> BMP, or FGF signaling on osteogenic differentiation of pASC and pBMSC after facultative BMP-2 supplementation. Exemplary microscopic representation of alizarin red S staining in pASC and pBMSC after 28 days of differentiation with (A) OM and (B) addition of BMP-2 (450 ng/mL) with the inhibitors SB431542, dorsomorphin, and BGJ398 (scale bar = 200 um). (C,D) Photomercial quantification of the osseous differentiation of pASC and pBMSC cultured with OM +/−BMP-2 for up to 28 days in addition to the inhibitors SB431542, dorsomorphin, and BGJ398. Significant differences are marked (* p ≤0.05, ** p ≤0.01, *** p ≤0.001; pASC n = 6; pBMSC n = 4; BMP-2 [450 ng/mL]; SB431542 [1 µM]; dorsomorphin [0.5 µM]; BGJ398 [0.5 µM]).
    Tgf β2 Rii, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 13 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tgf+%CE%B22+rii/pm40563862-64-23-45?v=R%26D+Systems
    Average 93 stars, based on 13 article reviews
    tgf β2 rii - by Bioz Stars, 2026-07
    93/100 stars

    Images

    1) Product Images from "BMP-2-Driven Osteogenesis: A Comparative Analysis of Porcine BMSCs and ASCs and the Role of TGF-β and FGF Signaling."

    Article Title: BMP-2-Driven Osteogenesis: A Comparative Analysis of Porcine BMSCs and ASCs and the Role of TGF-β and FGF Signaling.

    Journal: Biology

    doi: 10.3390/biology14060610

    Figure 3. Effects of co-inhibition of TGF-B, BMP, or FGF signaling on osteogenic differentiation of pASC and pBMSC after facultative BMP-2 supplementation. Exemplary microscopic representation of alizarin red S staining in pASC and pBMSC after 28 days of differentiation with (A) OM and (B) addition of BMP-2 (450 ng/mL) with the inhibitors SB431542, dorsomorphin, and BGJ398 (scale bar = 200 um). (C,D) Photomercial quantification of the osseous differentiation of pASC and pBMSC cultured with OM +/−BMP-2 for up to 28 days in addition to the inhibitors SB431542, dorsomorphin, and BGJ398. Significant differences are marked (* p ≤0.05, ** p ≤0.01, *** p ≤0.001; pASC n = 6; pBMSC n = 4; BMP-2 [450 ng/mL]; SB431542 [1 µM]; dorsomorphin [0.5 µM]; BGJ398 [0.5 µM]).
    Figure Legend Snippet: Figure 3. Effects of co-inhibition of TGF-B, BMP, or FGF signaling on osteogenic differentiation of pASC and pBMSC after facultative BMP-2 supplementation. Exemplary microscopic representation of alizarin red S staining in pASC and pBMSC after 28 days of differentiation with (A) OM and (B) addition of BMP-2 (450 ng/mL) with the inhibitors SB431542, dorsomorphin, and BGJ398 (scale bar = 200 um). (C,D) Photomercial quantification of the osseous differentiation of pASC and pBMSC cultured with OM +/−BMP-2 for up to 28 days in addition to the inhibitors SB431542, dorsomorphin, and BGJ398. Significant differences are marked (* p ≤0.05, ** p ≤0.01, *** p ≤0.001; pASC n = 6; pBMSC n = 4; BMP-2 [450 ng/mL]; SB431542 [1 µM]; dorsomorphin [0.5 µM]; BGJ398 [0.5 µM]).

    Techniques Used: Inhibition, Staining, Cell Culture

    Figure 4. The effects of inhibitor combinations on osteogenic differentiation of pASC and pBMSC. Photometrical quantification of osseous differentiation of (A) pASCs and (B) pBMSCs. Cells were cultured in OM +/−BMP-2 with combined addition of respective inhibitors SB431542, dorsomorphin, and BGJ398. Combined utilization of SB431542 (TGF-inhibitor) and BGJ398 (FGF-inhibitor) showed the highest results in both pASC and pBMSC. Significant differences are marked (* p ≤0.05, ** p ≤0.01; pASC n = 6; pBMSC n = 4; BMP-2 [450 ng/mL]; SB431542 [1 µM]; dorsomorphin [0.5 µM]; BGJ398 [0.5 µM].
    Figure Legend Snippet: Figure 4. The effects of inhibitor combinations on osteogenic differentiation of pASC and pBMSC. Photometrical quantification of osseous differentiation of (A) pASCs and (B) pBMSCs. Cells were cultured in OM +/−BMP-2 with combined addition of respective inhibitors SB431542, dorsomorphin, and BGJ398. Combined utilization of SB431542 (TGF-inhibitor) and BGJ398 (FGF-inhibitor) showed the highest results in both pASC and pBMSC. Significant differences are marked (* p ≤0.05, ** p ≤0.01; pASC n = 6; pBMSC n = 4; BMP-2 [450 ng/mL]; SB431542 [1 µM]; dorsomorphin [0.5 µM]; BGJ398 [0.5 µM].

    Techniques Used: Cell Culture



    Similar Products

    tgf β2 rii  (R&D Systems)
    93
    R&D Systems tgf β2 rii
    Figure 3. Effects of co-inhibition of <t>TGF-B,</t> BMP, or FGF signaling on osteogenic differentiation of pASC and pBMSC after facultative BMP-2 supplementation. Exemplary microscopic representation of alizarin red S staining in pASC and pBMSC after 28 days of differentiation with (A) OM and (B) addition of BMP-2 (450 ng/mL) with the inhibitors SB431542, dorsomorphin, and BGJ398 (scale bar = 200 um). (C,D) Photomercial quantification of the osseous differentiation of pASC and pBMSC cultured with OM +/−BMP-2 for up to 28 days in addition to the inhibitors SB431542, dorsomorphin, and BGJ398. Significant differences are marked (* p ≤0.05, ** p ≤0.01, *** p ≤0.001; pASC n = 6; pBMSC n = 4; BMP-2 [450 ng/mL]; SB431542 [1 µM]; dorsomorphin [0.5 µM]; BGJ398 [0.5 µM]).
    Tgf β2 Rii, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tgf+%CE%B22+rii/pm40563862-64-23-45?v=R%26D+Systems
    Average 93 stars, based on 1 article reviews
    tgf β2 rii - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    tgf β2  (R&D Systems Hematology)
    94
    R&D Systems Hematology tgf β2
    Figure 3. Effects of co-inhibition of <t>TGF-B,</t> BMP, or FGF signaling on osteogenic differentiation of pASC and pBMSC after facultative BMP-2 supplementation. Exemplary microscopic representation of alizarin red S staining in pASC and pBMSC after 28 days of differentiation with (A) OM and (B) addition of BMP-2 (450 ng/mL) with the inhibitors SB431542, dorsomorphin, and BGJ398 (scale bar = 200 um). (C,D) Photomercial quantification of the osseous differentiation of pASC and pBMSC cultured with OM +/−BMP-2 for up to 28 days in addition to the inhibitors SB431542, dorsomorphin, and BGJ398. Significant differences are marked (* p ≤0.05, ** p ≤0.01, *** p ≤0.001; pASC n = 6; pBMSC n = 4; BMP-2 [450 ng/mL]; SB431542 [1 µM]; dorsomorphin [0.5 µM]; BGJ398 [0.5 µM]).
    Tgf β2, supplied by R&D Systems Hematology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tgf+%CE%B22+rii/pmc10844250-190-15-16?v=R%26D+Systems+Hematology
    Average 94 stars, based on 1 article reviews
    tgf β2 - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 3. Effects of co-inhibition of TGF-B, BMP, or FGF signaling on osteogenic differentiation of pASC and pBMSC after facultative BMP-2 supplementation. Exemplary microscopic representation of alizarin red S staining in pASC and pBMSC after 28 days of differentiation with (A) OM and (B) addition of BMP-2 (450 ng/mL) with the inhibitors SB431542, dorsomorphin, and BGJ398 (scale bar = 200 um). (C,D) Photomercial quantification of the osseous differentiation of pASC and pBMSC cultured with OM +/−BMP-2 for up to 28 days in addition to the inhibitors SB431542, dorsomorphin, and BGJ398. Significant differences are marked (* p ≤0.05, ** p ≤0.01, *** p ≤0.001; pASC n = 6; pBMSC n = 4; BMP-2 [450 ng/mL]; SB431542 [1 µM]; dorsomorphin [0.5 µM]; BGJ398 [0.5 µM]).

    Journal: Biology

    Article Title: BMP-2-Driven Osteogenesis: A Comparative Analysis of Porcine BMSCs and ASCs and the Role of TGF-β and FGF Signaling.

    doi: 10.3390/biology14060610

    Figure Lengend Snippet: Figure 3. Effects of co-inhibition of TGF-B, BMP, or FGF signaling on osteogenic differentiation of pASC and pBMSC after facultative BMP-2 supplementation. Exemplary microscopic representation of alizarin red S staining in pASC and pBMSC after 28 days of differentiation with (A) OM and (B) addition of BMP-2 (450 ng/mL) with the inhibitors SB431542, dorsomorphin, and BGJ398 (scale bar = 200 um). (C,D) Photomercial quantification of the osseous differentiation of pASC and pBMSC cultured with OM +/−BMP-2 for up to 28 days in addition to the inhibitors SB431542, dorsomorphin, and BGJ398. Significant differences are marked (* p ≤0.05, ** p ≤0.01, *** p ≤0.001; pASC n = 6; pBMSC n = 4; BMP-2 [450 ng/mL]; SB431542 [1 µM]; dorsomorphin [0.5 µM]; BGJ398 [0.5 µM]).

    Article Snippet: The respective conjugated antibodies were used for the expressions of ALK3 (Cat. No.: AF436), ALK 5 (Cat. No.: FAB5871), ALK6 (Cat. No.: FAB5051A), TGF-β2-RII (Cat. No.: FAB532P), ALK7 (Cat. No.: FAB77491A), ALK2 (Cat. No.: AF637), ALK4 (Cat. No.: MAB2221), and BMPR-II (Cat. No.: AF811) (by R&D Systems, Minneapolis, MN, USA), and the pASCs and pBMSCs were compared for their expressions of the specific surface antigens CD45 (Cat. No.: MCA1568GA, BioRad, Hercules, CA, USA), HLA-DR (human leukocyte antigen–antigen D-related surface molecule) (Cat. No.: MCA2314F, Bio-Rad, Hercules, CA, USA), CD29 (Cat. No.: 561,496, BD Pharmingen, Franklin Lakes, NJ, USA), CD79alpha (Bio-Rad, Cat. No.: MCA2538GA), CD14 (Cat. No.: MCA1568GA, Bio-Rad, Hercules, CA, USA), CD31 (Cat. No.: AF3387, R&D Systems, Minneapolis, MN, USA), CD105 (Cat. No.: NB110-58718APC, Novus Biologicals, Minneapolis, MN, USA), CD26 (, Cat. No.: NB600-552APC, Novus Biologicals, Minneapolis, MN, USA), CD73 (, Cat. No.: AF4488, R&D Systems, Minneapolis, MN, USA), CD90 (Cat. No.: 559,869, BD Pharmingen, Franklin Lakes, NJ, USA), CD34 (Cat. No.: 81289, abcam, Cambridge, UK), and CD44 (Cat. No.: 5531, BD Pharmingen, Franklin Lakes, NJ, USA).

    Techniques: Inhibition, Staining, Cell Culture

    Figure 4. The effects of inhibitor combinations on osteogenic differentiation of pASC and pBMSC. Photometrical quantification of osseous differentiation of (A) pASCs and (B) pBMSCs. Cells were cultured in OM +/−BMP-2 with combined addition of respective inhibitors SB431542, dorsomorphin, and BGJ398. Combined utilization of SB431542 (TGF-inhibitor) and BGJ398 (FGF-inhibitor) showed the highest results in both pASC and pBMSC. Significant differences are marked (* p ≤0.05, ** p ≤0.01; pASC n = 6; pBMSC n = 4; BMP-2 [450 ng/mL]; SB431542 [1 µM]; dorsomorphin [0.5 µM]; BGJ398 [0.5 µM].

    Journal: Biology

    Article Title: BMP-2-Driven Osteogenesis: A Comparative Analysis of Porcine BMSCs and ASCs and the Role of TGF-β and FGF Signaling.

    doi: 10.3390/biology14060610

    Figure Lengend Snippet: Figure 4. The effects of inhibitor combinations on osteogenic differentiation of pASC and pBMSC. Photometrical quantification of osseous differentiation of (A) pASCs and (B) pBMSCs. Cells were cultured in OM +/−BMP-2 with combined addition of respective inhibitors SB431542, dorsomorphin, and BGJ398. Combined utilization of SB431542 (TGF-inhibitor) and BGJ398 (FGF-inhibitor) showed the highest results in both pASC and pBMSC. Significant differences are marked (* p ≤0.05, ** p ≤0.01; pASC n = 6; pBMSC n = 4; BMP-2 [450 ng/mL]; SB431542 [1 µM]; dorsomorphin [0.5 µM]; BGJ398 [0.5 µM].

    Article Snippet: The respective conjugated antibodies were used for the expressions of ALK3 (Cat. No.: AF436), ALK 5 (Cat. No.: FAB5871), ALK6 (Cat. No.: FAB5051A), TGF-β2-RII (Cat. No.: FAB532P), ALK7 (Cat. No.: FAB77491A), ALK2 (Cat. No.: AF637), ALK4 (Cat. No.: MAB2221), and BMPR-II (Cat. No.: AF811) (by R&D Systems, Minneapolis, MN, USA), and the pASCs and pBMSCs were compared for their expressions of the specific surface antigens CD45 (Cat. No.: MCA1568GA, BioRad, Hercules, CA, USA), HLA-DR (human leukocyte antigen–antigen D-related surface molecule) (Cat. No.: MCA2314F, Bio-Rad, Hercules, CA, USA), CD29 (Cat. No.: 561,496, BD Pharmingen, Franklin Lakes, NJ, USA), CD79alpha (Bio-Rad, Cat. No.: MCA2538GA), CD14 (Cat. No.: MCA1568GA, Bio-Rad, Hercules, CA, USA), CD31 (Cat. No.: AF3387, R&D Systems, Minneapolis, MN, USA), CD105 (Cat. No.: NB110-58718APC, Novus Biologicals, Minneapolis, MN, USA), CD26 (, Cat. No.: NB600-552APC, Novus Biologicals, Minneapolis, MN, USA), CD73 (, Cat. No.: AF4488, R&D Systems, Minneapolis, MN, USA), CD90 (Cat. No.: 559,869, BD Pharmingen, Franklin Lakes, NJ, USA), CD34 (Cat. No.: 81289, abcam, Cambridge, UK), and CD44 (Cat. No.: 5531, BD Pharmingen, Franklin Lakes, NJ, USA).

    Techniques: Cell Culture